Dimethyl fumarate

(Tecfidera)

Dimethyl fumarate

Drug updated on 11/10/2023

Dosage FormCapsule (oral; 120 mg, 240 mg)
Drug ClassImmunosuppressants
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Product Monograph / Prescribing Information

Document TitleYearSource
Tecfidera (dimethyl fumarate) Prescribing Information.2022Biogen Idec Inc., Cambridge, MA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Dimethyl Fumarate or Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A Meta-analysis of Post-marketing Studies.2023Neurotherapeutics
Disease modifying therapy and pregnancy outcomes in multiple sclerosis: A systematic review and meta-analysis.2023Journal of Neuroimmunology
Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value.2022ICER
Association of Disease-Modifying Therapies with COVID-19 Susceptibility and Severity in Patients with Multiple Sclerosis: A Systematic Review and Network Meta-Analysis.2022Multiple Sclerosis International
Post marketing new adverse effects of oral therapies in multiple sclerosis: A systematic review.2022Multiple Sclerosis and Related Disorders
Disease modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.2021Autoimmunity Reviews
Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.2021CNS Drugs
Safety of dimethyl fumarate for multiple sclerosis: A systematic review and meta-analysis. 2020Multiple Sclerosis and Related Disorders
Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis. 2020Journal of Neurology
Disease modifying therapies in multiple sclerosis: cost-effectiveness systematic review.2020Farmacia Hospitalaria
Benefit-risk of therapies for relapsing-remitting multiple sclerosis: testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat to Harm (NNTH) and the likelihood to be helped or harmed (LHH): a systematic review and meta-analysis.. 2020CNS Drugs
Adverse psychiatric effects of disease-modifying therapies in multiple sclerosis: a systematic review.2018Multiple Sclerosis and Related Disorders

Clinical Practice Guidelines